Hostname: page-component-7b7567c8c-9cwtv Total loading time: 0 Render date: 2026-11-19T12:49:14.975Z Has data issue: false hasContentIssue false

Antibiotic utilization trends in Veterans Affairs patients with Stenotrophomonas maltophilia bloodstream infections

Published online by Cambridge University Press:  09 September 2024

Clara H. Lee
Affiliation:
Department of Pharmacy, San Francisco VA Health Care System, San Francisco, CA, USA
Ursula C. Patel
Affiliation:
Department of Pharmacy, Edward Hines, Jr. VA Hospital, Hines, IL, USA
Amanda Vivo
Affiliation:
Center of Innovation for Complex Chronic Healthcare, Edward Hines, Jr. VA Hospital, Hines, IL, USA
Lishan Cao
Affiliation:
Center of Innovation for Complex Chronic Healthcare, Edward Hines, Jr. VA Hospital, Hines, IL, USA
Charlesnika T. Evans*
Affiliation:
Center of Innovation for Complex Chronic Healthcare, Edward Hines, Jr. VA Hospital, Hines, IL, USADepartment of Preventive Medicine, Center for Health Services and Outcomes Research, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
*
Corresponding author: Charlesnika T. Evans; Email: charlesnika.evans@va.gov

Abstract

Objective:

Stenotrophomonas maltophilia is a multidrug-resistant gram-negative bacillus that can cause serious infections but has limited treatment options. This study aims to establish trends in the treatment of S. maltophilia bloodstream infections (BSI) across the United States in Department of Veterans Affairs (VA) facilities.

Methods:

Data was evaluated over a 10-year timeframe (2012 to 2021) in this retrospective cohort study. Veterans with ≥ 1 blood culture with S. maltophilia within a VA medical encounter were included. Microbiology, pharmacy, and patient information were collected through national VA data sources and chart review. Descriptive statistics and Poisson regression were used to summarize patient demographics, facility characteristics, microbiologic data, and treatment trends.

Results:

A total of 374 blood cultures positive for S. maltophilia were identified across 75 VA facilities. Of 282 unique patients with BSI, the majority were male (93.6%), white (67.4%), with a mean age of 64 ± 13.1 years. Of those patients, 78% received treatment, 12.8% had a polymicrobial blood culture, and 5.3% had a documented sulfa allergy. Susceptibility results were most reported for trimethoprim-sulfamethoxazole (TMP-SMX), levofloxacin, and ceftazidime, with 4.5%, 4.3%, and 44.4% resistant isolates, respectively. Antibiotics most prescribed included TMP-SMX (41.5%) and levofloxacin (39.4%), followed by ciprofloxacin (13.8%) and ceftazidime (12.4%). Combination therapy was prescribed in 33% of patients. No significant trends were found with antibiotic utilization over time.

Conclusions:

TMP-SMX and levofloxacin were the most prescribed antibiotics for S. maltophilia BSI treatment. No significant changes were seen with antibiotic prescribing trends in Veterans from 2012 to 2021.

Information

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Table 1.Patient and facility characteristics associated with S. maltophilia bacteremia

Figure 1

Figure 1.Frequency of resistant S. maltophilia isolates to commonly tested antibiotics.

Figure 2

Table 2.Antimicrobial treatment for S. maltophilia BSI

Figure 3

Figure 2.Frequencies of S. maltophilia positive blood cultures by year across 75 VA facilities.

Figure 4

Figure 3.Trends in prescribing of the most commonly used agents for S. maltophilia BSI in Veterans from 2012 to 2021.